ATAMESTANE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C20H26O2
Molecular Weight	298.4192
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C(C)[C@]34C

InChI

InChIKey=PEPMWUSGRKINHX-TXTPUJOMSA-N

InChI=1S/C20H26O2/c1-12-10-14(21)11-13-4-5-15-16-6-7-18(22)19(16,2)9-8-17(15)20(12,13)3/h10-11,15-17H,4-9H2,1-3H3/t15-,16-,17-,19-,20-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C20H26O2
Molecular Weight	298.4192
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17971594 | http://adisinsight.springer.com/drugs/800002517 | https://www.ncbi.nlm.nih.gov/pubmed/1722797 | https://www.ncbi.nlm.nih.gov/pubmed/7682838

Atamestane is a new, competitive, and irreversible inhibitor of estrogen biosynthesis. It is an aromatase inhibitor. Atamestane lacks other intrinsic hormonal or antihormonal activities and shows no inhibition of other cytochrome-P450 dependent enzymes of adrenal steroidogenesis. It had been in phase III clinical trial for the treatment of breast cancer and phase II for the treatment of benign prostatic hyperplasia. It was discontinued from development after an 865-patient trial in breast cancer showed no improvement in efficacy over letrozole.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Aromatase 8 Target ID: P11511 Gene ID: 1588.0 Gene Symbol: CYP19A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7682838	Inhibitor 8297		0.4 µM [EC50]

Conditions

Condition	Modality	Highest Phase	Product
Breast cancer 434 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17971594	Primary	Phase III 656	Unknown Approved Use Unknown
Benign prostatic hyperplasia 28 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7545721 https://www.ncbi.nlm.nih.gov/pubmed/7541854	Primary	Phase II 1132	Unknown Approved Use Unknown
Physical frailty 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16804050 http://www.ergo-log.com/dheaplusatamestane.html	Primary	Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
An alpha-fetoprotein-derived peptide reduces the uterine hyperplasia and increases the antitumour effect of tamoxifen.	2007 Aug 6	17637684
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy.	2007 Jul	17588628
Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.	2007 Nov 1	17971594

Patents

Sample Use Guides

In Vivo Use Guide

Atamestane is administered over 48 weeks as a daily dose of 100 mg or 300 mg.

Route of Administration: Oral

In Vitro Use Guide

The levels of aromatase mRNA was 6.31 amol/ug total RNA in JEG-3 cells, cultured in the presence or absence of 10 uM Atamestane at 37°C for 24 h.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 16:45:40 GMT 2023` Edited by `admin` on `Sat Dec 16 16:45:40 GMT 2023`
Record UNII	62GA3K28B6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ATAMESTANE

Official Name

English

SH-489

Code

English

atamestane [INN]

Common Name

English

1-METHYLANDROSTA-1,4-DIENE-3,17-DIONE

Systematic Name

English

Atamestane [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2017